Cancer stem cells (CSCs) exhibit specific characteristics including decontrolled self-renewal,
tumor-initiating, promoting, and metastatic potential, abnormal stemness signaling, and
chemotherapy resistance. Thus, targeting CSC is becoming an emerging
cancer treatment. α-
Mangostin has been shown to have potent and multiple anticancer activities. Accordingly, we hypothesized that α-
mangostin may diminish the stemness and proliferation of CSC-like
cervical cancer cells. In our results, comparing to the parent cells, CSC-like SiHa and HeLa cells highly expressed CSC marker Sox2, Oct4, Nanog,
CK-17, and CD49f. α-
Mangostin significantly reduced the cell viability, sphere-forming ability, and expression of the CSC stemness makers of CSC-like
cervical cancer cells. Further investigation showed that α-
mangostin induced mitochondrial depolarization and mitochondrial apoptosis signaling, including upregulation of Bax, downregulation of Mcl-1 and Bcl-2, and activation of
caspase-9/3. Moreover, α-
mangostin synergically enhanced the cytotoxicity of
cisplatin on CSC-like SiHa cells by promoting mitochondrial apoptosis and inhibiting the expression of CSC markers. Consistent with in vitro findings, in vivo
tumor growth assay revealed that α-
mangostin administration significantly inhibited the growth of inoculated CSC-like SiHa cells and synergically enhanced the antitumor effect of
cisplatin. Our findings indicate that α-
mangostin can reduce the stemness and proliferation of CSC-like SiHa and HeLa cells and promote the cytotoxicity of
cisplatin, which may attribute to the mitochondrial apoptosis activation. Thus, it suggests that α-
mangostin may have clinical potential to improve
chemotherapy for
cervical cancer by targeting cervical CSC.